Compositions and methods for treating depression
Disclosed are a novel combination of specific therapeutics selected from S-adenosyl methionine or a salt thereof, folic acid or a metabolite or salt thereof, and one or more omega-3 fatty acids or salts thereof, useful for a variety of conditions, as discussed herein. Methods of treatment include the treatment of neuropsychiatric conditions, such as depression.
1. A method of treating a mood disorder selected from group consisting of depression, bipolar disorder, anxiety disorder, and hormonal mood swings, the method consisting of administering to a subject in need thereof a therapeutically effective amount of:
S-adenosyl methionine or a salt thereof, wherein S-adenosyl methionine or a salt thereof is provided in a range of between about 800 mg to about 1600 mg, inclusive;
methyl folate or a salt thereof, wherein methyl folate of a salt thereof is provided in a range between about 5 mg to about 20 mg, inclusive; and
one or more omega-3 fatty acids or salts thereof, wherein the omega-3 fatty acids or salts thereof are provided in a range of between about 500 mg to about 1800 mg, inclusive, and the one or more omega-3 fatty acids or salts thereof comprises at least 60% EPA; to a subject in need thereof.
2. The method of claim 1 , wherein the method consists of administering S-adenosyl methionine or a salt thereof and methyl folate or a salt thereof together in the same composition, and administering the one or more omega-3 fatty acids or salts thereof in a separate composition.
3. The method of claim 1 , wherein the method consists of administering each of S-adenosyl methionine or a salt thereof, methyl folate or a salt thereof, and one or more omega-3 fatty acids or salts thereof in separate compositions.
4. The method of claim 1 , wherein the step of administering is orally administering.
5. The method of claim 1 , wherein the omega-3 fatty acids or salts thereof is provided in a range of between about 800 mg to about 1600 mg, inclusive.
6. The method of claim 1 , wherein the one or more omega-3 fatty acids or salts thereof is selected from EPA, DHA, or a combination thereof.
7. The method of claim 1 , wherein the subject is receiving or has received a prescription anti-depressant.
8. The method of claim 7 , wherein the prescription anti-depressant is administered to the subject in an amount not effective to treat the disorder when administered alone.
9. The method of claim 7 , wherein the prescription anti-depressant causes or is likely to cause an adverse side effect or undesired side effect in the subject.
10. The method of claim 7 , wherein the subject is a non-responder to the prescription anti-depressant.
11. The method of claims 1 , wherein the subject is a mammal.
12. The method of claim 11 , wherein the mammal is a human subject.
13. The method of claim 12 , wherein the human subject is 24 years of age or younger.
14. The method of claims 1 , wherein the subject is at risk of suicide when administered an SSRI.
15. The method of claims 1 , wherein the subject is not diagnosed with a bipolar disorder and has not exhibited an episode of mania.
16. The method of claims 1 , wherein the subject has an Anxiety Disorder.
17. The method of claim 1 , wherein the subject has depression.
18. The method of claim 1 , wherein the neuropsychiatric condition is selected from mood disorders or conditions characterized by atypical mood.
19. The method of claim 1 , wherein depression is Major Depressive Disorder.
20. The method of claim 1 , wherein the hormonal mood swings is selected from mood swings during pregnancy, during post-partum, during puberty, during menopause, or are a result of a Premenstrual Dysphoric Disorder or related condition.